EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+4.61%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$3.29B
AUM Growth
+$3.29B
(+13%)
Cap. Flow
+$368M
Cap. Flow
% of AUM
11.2%
Top 10 Holdings %
Top 10 Hldgs %
35.01%
Holding
144
New
13
Increased
43
Reduced
17
Closed
25
Top Buys
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
$45.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.2M |
| 3 |
Exact Sciences
EXAS
|
$41.9M |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
$36.4M |
| 5 |
Idexx Laboratories
IDXX
|
$28.3M |
Top Sells
| 1 |
BLUE
bluebird bio
BLUE
|
$32.9M |
| 2 |
ALTR
Altair Engineering Inc. Class A Common Stock
ALTR
|
$23.1M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$22.9M |
| 4 |
uniQure
QURE
|
$21.8M |
| 5 |
WBC
WABCO HOLDINGS INC.
WBC
|
$17.7M |
Sector Composition
| 1 | Healthcare | 47.89% |
| 2 | Technology | 19.59% |
| 3 | Industrials | 8.32% |
| 4 | Consumer Discretionary | 7.68% |
| 5 | Communication Services | 3.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $196M | 5.95% | 1,698,648 | – | – |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $171M | 5.19% | 1,123,000 +277,832 | +33% | +$42.2M |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $138M | 4.2% | 755,000 -50,000 | -6% | -$9.15M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $136M | 4.13% | 2,841,300 +946,300 | +50% | +$45.2M |
|
5
Twilio
TWLO
$16.2B
| $113M | 3.43% | 827,000 | – | – |
|
6
Trade Desk
TTD
$26.7B
| $110M | 3.33% | 481,000 | – | – |
|
7
Roper Technologies
ROP
$56.6B
| $78.4M | 2.38% | 214,000 +37,000 | +21% | +$13.6M |
|
8
Waste Connections
WCN
$47.5B
| $76.8M | 2.34% | 804,000 +202,000 | +34% | +$19.3M |
|
9
Wayfair
W
$9.67B
| $75.2M | 2.28% | 514,777 | – | – |
|
10
Lowe's Companies
LOW
$145B
| $58.7M | 1.78% | 581,800 +16,800 | +3% | +$1.7M |
|
11
Palo Alto Networks
PANW
$127B
| $58.5M | 1.78% | 287,000 +75,000 | +35% | +$15.3M |
|
|
12
Exact Sciences
EXAS
$8.98B
| $58.4M | 1.78% | 495,000 +355,000 | +254% | +$41.9M |
|
13
Mettler-Toledo International
MTD
$26.8B
| $57.9M | 1.76% | 68,900 +20,900 | +44% | +$17.6M |
|
|
AIMT
14
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $57.8M | 1.76% | 2,775,000 +813,000 | +41% | +$16.9M |
|
15
Xylem
XYL
$34.5B
| $57.1M | 1.74% | 682,900 +285,900 | +72% | +$23.9M |
|
16
HubSpot
HUBS
$25.5B
| $54.1M | 1.64% | 317,000 | – | – |
|
|
SPLK
17
DELISTED
Splunk Inc
SPLK
| $53.8M | 1.64% | 428,000 | – | – |
|
18
FIVE9
FIVN
$2.08B
| $51.3M | 1.56% | 1,000,000 +189,000 | +23% | +$9.69M |
|
19
Dianthus Therapeutics
DNTH
$759M
| $50.8M | 1.54% | 3,495,239 +425,000 | +14% | +$6.18M |
|
|
STML
20
DELISTED
Stemline Therapeutics, Inc.
STML
| $48.9M | 1.49% | 3,192,727 +1,583,204 | +98% | +$24.3M |
|
|
BPMC
21
DELISTED
Blueprint Medicines
BPMC
| $43.6M | 1.32% | 462,000 | – | – |
|
22
Lam Research
LRCX
$127B
| $42.6M | 1.3% | 227,000 | – | – |
|
23
Vulcan Materials
VMC
$38.5B
| $41.9M | 1.27% | 305,000 +46,000 | +18% | +$6.32M |
|
24
Crown Castle
CCI
$43.2B
| $41.6M | 1.26% | 319,000 +19,000 | +6% | +$2.48M |
|
25
Lennox International
LII
$19.6B
| $39.6M | 1.2% | 144,000 | – | – |
|